Remibrutinib (Rhapsido)

What is remibrutinib?

Remibrutinib (Rhapsido) is an oral medication used for chronic spontaneous urticaria, also called chronic hives, in adults who continue to have symptoms despite antihistamine treatment. It offers a non-injection option for some adults with persistent hives.

That can make it appealing for patients who have ongoing breakthrough hives, swelling, or itch but would prefer not to move directly to an injectable treatment.

How does remibrutinib work?

Remibrutinib works by blocking Bruton's tyrosine kinase, often shortened to BTK. This helps reduce signaling involved in mast-cell activation and histamine release, which are important parts of the process that drives chronic hives.

Because it works differently from antihistamines, it may be discussed when standard antihistamine-based treatment has not provided enough control.

What are possible side effects of remibrutinib?

Possible side effects can include:

• Headache

• Upper respiratory symptoms

• Bruising, nosebleeds, gum bleeding, or other bleeding-related symptoms in some patients

• Laboratory abnormalities in some cases

Because bleeding events are part of the label-level safety discussion for this medication, patients should review blood thinner use, other medication interactions, and procedure planning with the prescribing clinician.

How is remibrutinib used?

Remibrutinib is taken by mouth on a schedule directed by your provider. It is generally used when antihistamines have not been enough to control chronic spontaneous urticaria.

This medication may need to be held before and after certain surgeries or invasive procedures, so treatment timing should be reviewed with your provider when procedures are planned. Your clinician may also review liver tests, other medications, and bleeding-related risks before starting treatment.